RBR-3vcg568招募中3 期

The use of Dapagliflozin in Lupus Nephritis patients with residual proteinuria

Hospital das Clínicas/Empresa Brasileira de Serviços Hospitalares/Universidade Federal de Pernambuco0 个研究点开始时间: 2023年3月6日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Adults; both genders; patients with class III, IV and/or V inactive Lupus Nephritis with proteinuria >500mg/24h and/or urine abumin/creatinine ratio > 200mg/g and estimated glomerular filtration rate > 20ml/min; use of stable maintenance immunosuppression > 4 weeks

•Active lupus nephritis (activity index >2 on biopsy less than 12 months old); induction treatment with Cyclophosphamide, Mycophenolate Mofetil >2g/day or associated Cyclosporine regimen; patients with a history of recurrent urinary tract infection (more than 3 episodes per year); clinical or laboratory suspicion of renal or extra-renal lupus activity requiring increased immunosuppression in the last 6 months; use of prednisone at doses greater than 20mg/day for more than 15 days; patients with type 1 or 2 diabetes with Diabetic Nephropathy on renal biopsy; patients with chronic kidney disease of another etiology

发起方

Hospital das Clínicas/Empresa Brasileira de Serviços Hospitalares/Universidade Federal de Pernambuco